Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04781192 · ClinicalTrials.gov registry record · Phase 1
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
A Phase 1 study of Advanced Biliary Tract Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT04781192 is a Phase 1 study of Advanced Biliary Tract Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 40 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT04781192, a Phase 1 study of Advanced Biliary Tract Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment
Conditions Studied
Interventions
- DRUG Regorafenib
- DRUG Durvalumab
Study Locations (5)
Missouri
- University of Kansas Cancer Center - North - Kansas City
- University of Kansas Cancer Center - Lee's Summit - Lee's Summit
- The University of Kansas Medical Center - North Kansas City
Kansas
- University of Kansas Cancer Center - Overland Park - Overland Park
- The University of Kansas Medical Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04781192
The ClinicalTrials.gov registry entry for NCT04781192 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Biliary Tract Cancer appearing as the primary indexed condition, and to 2 interventions - of which Regorafenib is the first listed.
NCT04781192 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Kansas.
Frequently Asked Questions
What is clinical trial NCT04781192 about?
NCT04781192 is a clinical study titled "The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers". The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment
What is the current status of trial NCT04781192?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-03-22. Estimated completion is 2026-12.
What conditions does trial NCT04781192 study?
This clinical trial studies the following conditions: Advanced Biliary Tract Cancer.
What interventions are being tested in trial NCT04781192?
The interventions under investigation include: Regorafenib (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT04781192?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04781192 being conducted?
This trial has 5 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RECRUITING · Phase 3
-
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.